Hib Vaccine
Hib meningitis · Hib pneumonia · Hib epiglottitis · Hib septicemia
Before the vaccine, Haemophilus influenzae type b was the leading cause of bacterial meningitis in children under 5 in developed countries. Hib meningitis carries a 3–6% fatality rate and causes permanent neurological damage — hearing loss, intellectual disability, seizure disorders — in 15–30% of survivors.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →The evidence moderately supports this vaccine for your child's situation. Benefits outweigh risks but some factors in your scenario lower the urgency.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Before the vaccine, Haemophilus influenzae type b was the leading cause of bacterial meningitis in children under 5 in developed countries. Hib meningitis carries a 3–6% fatality rate and causes permanent neurological damage — hearing loss, intellectual disability, seizure disorders — in 15–30% of survivors.
Hib meningitis survivors who escape death often face lifelong hearing loss (requiring hearing aids or cochlear implants), intellectual disability, epilepsy, or motor impairment. The disease is devastating in its swiftness — children can go from apparent health to coma within hours. Epiglottitis requires emergency intubation and ICU care.
🛡️ Vaccine Effectiveness
Immunity from conjugate vaccine is long-lasting. No booster required after complete infant series for immunocompetent children. Immunological memory well-documented.
Invasive Hib disease in vaccinated children is extremely rare. When it occurs, often in immunocompromised individuals or those who missed doses.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Children 15–59 months who never received Hib: 1 dose. Children 5+ generally not needed unless asplenic or immunocompromised.
⚖️ Benefits vs. Considerations
✓ Benefits
- One of the greatest success stories in vaccine history: >99% reduction in invasive Hib disease
- Prevents meningitis that kills or permanently disables 15–30% of children who contract it
- Exceptionally clean safety profile — among the lowest adverse event rates of any childhood vaccine
- 35 years of post-licensure safety data with no serious long-term safety signals identified
- Herd immunity effect protects unvaccinated infants before they complete the series
- Combination vaccines (Pentacel, Pediarix) mean no extra injection needed
↕ Considerations
- Disease has been so effectively controlled by vaccination that some parents may underestimate the ongoing need for the vaccine
- 4-dose series in first 15 months requires multiple visits
- If vaccination rates fall, Hib could re-emerge quickly (as seen in Alaska 1996–2008 in undervaccinated communities)
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- Some pediatric immunologists argue that a 3-dose schedule (as used in Finland and UK) is adequate, making the US 4-dose schedule conservative (Eskola et al., 1987 — Finnish RCT).
- In communities with very low Hib carriage rates due to high vaccine coverage, the incremental benefit of each additional dose may be very small, raising questions about schedule optimization.
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Duration of immunity in immunocompromised children (e.g., asplenic patients may need boosters)
- Whether a 3-dose series is equivalent to 4-dose for all children (some countries use 3-dose with good results)
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.